Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma

Kayo Sugimoto,Soo Ryang Kim,Soo Ki Kim,Susumu Imoto,Madoka Tohyama,Ke Ih Kim,Aya Ohtani,Takashi Hatae,Yoshihiko Yano,Masatoshi Kudo,Yoshitake Hayashi

Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma

2015

Kayo Sugimoto
Soo Ryang Kim
Soo Ki Kim
Susumu Imoto
Madoka Tohyama
Ke Ih Kim
Aya Ohtani
Takashi Hatae
Yoshihiko Yano
Masatoshi Kudo
Yoshitake Hayashi

Objectives: The efficacy of the all-oral administration of daclatasvir and asunaprevir for 24 weeks was compared with that of telaprevir for 12 weeks plus pegylat

Keywords:

Gastroenterology
Immunology
Telaprevir
Medicine
Hepatocellular carcinoma
Ribavirin
Daclatasvir
Viral load
Hepacivirus
Simeprevir
Virology
Internal medicine
Asunaprevir

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations